252 related articles for article (PubMed ID: 15841490)
1. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease.
Erdõs M; Uzvölgyi E; Nemes Z; Török O; Rákóczi E; Went-Sümegi N; Sümegi J; Maródi L
Hum Mutat; 2005 May; 25(5):506. PubMed ID: 15841490
[TBL] [Abstract][Full Text] [Related]
2. Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family.
Lewis J; Eiben LJ; Nelson DL; Cohen JI; Nichols KE; Ochs HD; Notarangelo LD; Duckett CS
Clin Immunol; 2001 Jul; 100(1):15-23. PubMed ID: 11414741
[TBL] [Abstract][Full Text] [Related]
3. Disease-causing SAP mutants are defective in ligand binding and protein folding.
Li C; Iosef C; Jia CY; Gkourasas T; Han VK; Shun-Cheng Li S
Biochemistry; 2003 Dec; 42(50):14885-92. PubMed ID: 14674764
[TBL] [Abstract][Full Text] [Related]
4. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4.
Sayós J; Nguyen KB; Wu C; Stepp SE; Howie D; Schatzle JD; Kumar V; Biron CA; Terhorst C
Int Immunol; 2000 Dec; 12(12):1749-57. PubMed ID: 11099315
[TBL] [Abstract][Full Text] [Related]
5. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome.
Tangye SG; Phillips JH; Lanier LL; Nichols KE
J Immunol; 2000 Sep; 165(6):2932-6. PubMed ID: 10975798
[TBL] [Abstract][Full Text] [Related]
6. Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase.
Aoukaty A; Tan R
J Biol Chem; 2002 Apr; 277(15):13331-7. PubMed ID: 11815622
[TBL] [Abstract][Full Text] [Related]
7. A "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome.
Hwang PM; Li C; Morra M; Lillywhite J; Muhandiram DR; Gertler F; Terhorst C; Kay LE; Pawson T; Forman-Kay JD; Li SC
EMBO J; 2002 Feb; 21(3):314-23. PubMed ID: 11823424
[TBL] [Abstract][Full Text] [Related]
8. Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors.
Chen R; Relouzat F; Roncagalli R; Aoukaty A; Tan R; Latour S; Veillette A
Mol Cell Biol; 2004 Jun; 24(12):5144-56. PubMed ID: 15169881
[TBL] [Abstract][Full Text] [Related]
9. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease.
Nichols KE; Ma CS; Cannons JL; Schwartzberg PL; Tangye SG
Immunol Rev; 2005 Feb; 203():180-99. PubMed ID: 15661030
[TBL] [Abstract][Full Text] [Related]
10. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
Parolini S; Bottino C; Falco M; Augugliaro R; Giliani S; Franceschini R; Ochs HD; Wolf H; Bonnefoy JY; Biassoni R; Moretta L; Notarangelo LD; Moretta A
J Exp Med; 2000 Aug; 192(3):337-46. PubMed ID: 10934222
[TBL] [Abstract][Full Text] [Related]
11. Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene.
Tóth B; Soltész B; Gyimesi E; Csorba G; Veres Á; Lányi Á; Kovács G; Maródi L; Erdős M
J Clin Immunol; 2015 Jan; 35(1):26-31. PubMed ID: 25491288
[TBL] [Abstract][Full Text] [Related]
12. Dual functional roles for the X-linked lymphoproliferative syndrome gene product SAP/SH2D1A in signaling through the signaling lymphocyte activation molecule (SLAM) family of immune receptors.
Li C; Iosef C; Jia CY; Han VK; Li SS
J Biol Chem; 2003 Feb; 278(6):3852-9. PubMed ID: 12458214
[TBL] [Abstract][Full Text] [Related]
13. SAP couples Fyn to SLAM immune receptors.
Chan B; Lanyi A; Song HK; Griesbach J; Simarro-Grande M; Poy F; Howie D; Sumegi J; Terhorst C; Eck MJ
Nat Cell Biol; 2003 Feb; 5(2):155-60. PubMed ID: 12545174
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immune activation and clinical events in acute infectious mononucleosis.
Williams H; Macsween K; McAulay K; Higgins C; Harrison N; Swerdlow A; Britton K; Crawford D
J Infect Dis; 2004 Jul; 190(1):63-71. PubMed ID: 15195244
[TBL] [Abstract][Full Text] [Related]
15. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A.
Li SC; Gish G; Yang D; Coffey AJ; Forman-Kay JD; Ernberg I; Kay LE; Pawson T
Curr Biol; 1999 Dec; 9(23):1355-62. PubMed ID: 10607564
[TBL] [Abstract][Full Text] [Related]
16. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines.
Nagy N; Cerboni C; Mattsson K; Maeda A; Gogolák P; Sümegi J; Lányi A; Székely L; Carbone E; Klein G; Klein E
Int J Cancer; 2000 Nov; 88(3):439-47. PubMed ID: 11054674
[TBL] [Abstract][Full Text] [Related]
17. [X-linked lymphoproliferative syndrome, EBV virus infection and defects in cytotoxicity lymphocyte regulation].
Malbrán A; Belmonte L; Ruibal-Ares B; Baré P; Bracco MM
Medicina (B Aires); 2003; 63(1):70-6. PubMed ID: 12673966
[TBL] [Abstract][Full Text] [Related]
18. Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients.
Ferrand V; Li C; Romeo G; Yin L
J Med Virol; 2003 May; 70(1):131-6. PubMed ID: 12629654
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients.
Morra M; Simarro-Grande M; Martin M; Chen AS; Lanyi A; Silander O; Calpe S; Davis J; Pawson T; Eck MJ; Sumegi J; Engel P; Li SC; Terhorst C
J Biol Chem; 2001 Sep; 276(39):36809-16. PubMed ID: 11477068
[TBL] [Abstract][Full Text] [Related]
20. Molecular and immunological basis of X-linked lymphoproliferative disease.
Latour S; Veillette A
Immunol Rev; 2003 Apr; 192():212-24. PubMed ID: 12670406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
